Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma

By Civallero Monica   Cosenza Maria   Bari Alessia   Sacchi Stefano  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 8, 2011-08 ,pp. : 1029-1031

Informa Healthcare

Access to resources Recommend Favorite

Oncologic, Endocrine & Metabolic Emerging drugs in B-cell non-Hodgkin's lymphoma

By Kassam Shireen   Montoto Silvia  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 2, 2008-06 ,pp. : 323-343

Informa Healthcare

Access to resources Recommend Favorite

Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin's lymphoma

By Tachi T.   Yasuda M.   Usui K.   Umeda M.   Nagaya K.   Osawa T.   Ichihashi A.   Noguchi Y.   Goto H.   Kasahara S.   Takahashi T.   Goto C.   Teramachi H.  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 10, 2015-10 ,pp. : 674-677

Govi-Verlag

Access to resources Recommend Favorite

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3465-3471

Blackwell Publishing

Access to resources Recommend Favorite

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma

By Jamal-Hanjani Mariam   Pettengell Ruth  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 11, 2011-11 ,pp. : 1441-1448

Informa Healthcare

Access to resources Recommend Favorite